Return on Tangible Equity: The amount of net income returned as a percentage of shareholders equity, after subtracting intangible assets, goodwill and preferred equity. Calculated as: Income from Continuing Operations / Tangible Shareholders Equity
Adial Pharmaceuticals, Inc. (ADIL) had Return on Tangible Equity of -324.68% for the most recently reported fiscal year, ending 2024-12-31.
| Income Statement Financials | |
-- |
|
$-13.20M |
|
-- |
|
-- |
|
$8.28M |
|
$-8.28M |
|
$-4.91M |
|
$-13.20M |
|
$-13.20M |
|
$-13.20M |
|
$-13.20M |
|
$-13.20M |
|
$-13.20M |
|
$-8.28M |
|
$-8.28M |
|
0.19M |
|
0.19M |
|
$-68.00 |
|
$-68.00 |
|
| Balance Sheet Financials | |
$4.06M |
|
-- |
|
$0.99M |
|
$5.04M |
|
$0.98M |
|
-- |
|
-- |
|
$0.98M |
|
$4.07M |
|
$4.06M |
|
$4.07M |
|
0.26M |
|
| Cash Flow Statement Financials | |
$-6.92M |
|
-- |
|
$7.85M |
|
$2.83M |
|
$3.75M |
|
$0.92M |
|
$0.80M |
|
-- |
|
-- |
|
| Fundamental Metrics & Ratios | |
4.16 |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
$-6.92M |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-324.42% |
|
|
Return on Tangible Equity |
-324.68% |
-261.65% |
|
-324.41% |
|
$15.71 |
|
$-35.67 |
|
$-35.67 |
|